COVID-19 Impact on Global Monoclonal Antibody for Multiple Myeloma Market Size, Status and Forecast 2020-2026

July 2020 | 93 pages | ID: C2905C5B94E8EN
QYResearch

Abstracts

This report focuses on the global Monoclonal Antibody for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Monoclonal Antibody for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Bristol Myers Squibb
• Abbvie
• Janssen Biotech
• Karyopharm Therapeutics
• PDL BioPharma
• Roche
• Seattle Genetics

Market segment by Type, the product can be split into

• Elotuzumab
• Daratumumab
• Siltuximab
• Dacetuzumab
• Rituximab
• Other

Market segment by Application, split into

• Hospital
• Drug Center
• Clinic
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Monoclonal Antibody for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.
• To present the Monoclonal Antibody for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Monoclonal Antibody for Multiple Myeloma are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Monoclonal Antibody for Multiple Myeloma Revenue
1.4 Market Analysis by Type
  1.4.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Elotuzumab
  1.4.3 Daratumumab
  1.4.4 Siltuximab
  1.4.5 Dacetuzumab
  1.4.6 Rituximab
  1.4.7 Other
1.5 Market by Application
  1.5.1 Global Monoclonal Antibody for Multiple Myeloma Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Drug Center
  1.5.4 Clinic
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Monoclonal Antibody for Multiple Myeloma Industry Impact
  1.6.1 How the Covid-19 is Affecting the Monoclonal Antibody for Multiple Myeloma Industry
    1.6.1.1 Monoclonal Antibody for Multiple Myeloma Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Monoclonal Antibody for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Monoclonal Antibody for Multiple Myeloma Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Monoclonal Antibody for Multiple Myeloma Market Perspective (2015-2026)
2.2 Monoclonal Antibody for Multiple Myeloma Growth Trends by Regions
  2.2.1 Monoclonal Antibody for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Monoclonal Antibody for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  2.2.3 Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Monoclonal Antibody for Multiple Myeloma Market Growth Strategy
  2.3.6 Primary Interviews with Key Monoclonal Antibody for Multiple Myeloma Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Monoclonal Antibody for Multiple Myeloma Players by Market Size
  3.1.1 Global Top Monoclonal Antibody for Multiple Myeloma Players by Revenue (2015-2020)
  3.1.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  3.1.3 Global Monoclonal Antibody for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio
  3.2.1 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody for Multiple Myeloma Revenue in 2019
3.3 Monoclonal Antibody for Multiple Myeloma Key Players Head office and Area Served
3.4 Key Players Monoclonal Antibody for Multiple Myeloma Product Solution and Service
3.5 Date of Enter into Monoclonal Antibody for Multiple Myeloma Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Monoclonal Antibody for Multiple Myeloma Historic Market Size by Type (2015-2020)
4.2 Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

5 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)
5.2 Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
6.2 Monoclonal Antibody for Multiple Myeloma Key Players in North America (2019-2020)
6.3 North America Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
6.4 North America Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
7.2 Monoclonal Antibody for Multiple Myeloma Key Players in Europe (2019-2020)
7.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
7.4 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

8 CHINA

8.1 China Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
8.2 Monoclonal Antibody for Multiple Myeloma Key Players in China (2019-2020)
8.3 China Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
8.4 China Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
9.2 Monoclonal Antibody for Multiple Myeloma Key Players in Japan (2019-2020)
9.3 Japan Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
9.4 Japan Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
10.2 Monoclonal Antibody for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
10.4 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

11 INDIA

11.1 India Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
11.2 Monoclonal Antibody for Multiple Myeloma Key Players in India (2019-2020)
11.3 India Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
11.4 India Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Monoclonal Antibody for Multiple Myeloma Market Size (2015-2020)
12.2 Monoclonal Antibody for Multiple Myeloma Key Players in Central & South America (2019-2020)
12.3 Central & South America Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020)
12.4 Central & South America Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Bristol Myers Squibb
  13.1.1 Bristol Myers Squibb Company Details
  13.1.2 Bristol Myers Squibb Business Overview and Its Total Revenue
  13.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Introduction
  13.1.4 Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020))
  13.1.5 Bristol Myers Squibb Recent Development
13.2 Abbvie
  13.2.1 Abbvie Company Details
  13.2.2 Abbvie Business Overview and Its Total Revenue
  13.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Introduction
  13.2.4 Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
  13.2.5 Abbvie Recent Development
13.3 Janssen Biotech
  13.3.1 Janssen Biotech Company Details
  13.3.2 Janssen Biotech Business Overview and Its Total Revenue
  13.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Introduction
  13.3.4 Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
  13.3.5 Janssen Biotech Recent Development
13.4 Karyopharm Therapeutics
  13.4.1 Karyopharm Therapeutics Company Details
  13.4.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
  13.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Introduction
  13.4.4 Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
  13.4.5 Karyopharm Therapeutics Recent Development
13.5 PDL BioPharma
  13.5.1 PDL BioPharma Company Details
  13.5.2 PDL BioPharma Business Overview and Its Total Revenue
  13.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Introduction
  13.5.4 PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
  13.5.5 PDL BioPharma Recent Development
13.6 Roche
  13.6.1 Roche Company Details
  13.6.2 Roche Business Overview and Its Total Revenue
  13.6.3 Roche Monoclonal Antibody for Multiple Myeloma Introduction
  13.6.4 Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
  13.6.5 Roche Recent Development
13.7 Seattle Genetics
  13.7.1 Seattle Genetics Company Details
  13.7.2 Seattle Genetics Business Overview and Its Total Revenue
  13.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Introduction
  13.7.4 Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
  13.7.5 Seattle Genetics Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Monoclonal Antibody for Multiple Myeloma Key Market Segments
Table 2. Key Players Covered: Ranking by Monoclonal Antibody for Multiple Myeloma Revenue
Table 3. Ranking of Global Top Monoclonal Antibody for Multiple Myeloma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Elotuzumab
Table 6. Key Players of Daratumumab
Table 7. Key Players of Siltuximab
Table 8. Key Players of Dacetuzumab
Table 9. Key Players of Rituximab
Table 10. Key Players of Other
Table 11. COVID-19 Impact Global Market: (Four Monoclonal Antibody for Multiple Myeloma Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Monoclonal Antibody for Multiple Myeloma Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Monoclonal Antibody for Multiple Myeloma Players to Combat Covid-19 Impact
Table 16. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Monoclonal Antibody for Multiple Myeloma Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Monoclonal Antibody for Multiple Myeloma Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Monoclonal Antibody for Multiple Myeloma Market Share by Regions (2015-2020)
Table 20. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Monoclonal Antibody for Multiple Myeloma Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Monoclonal Antibody for Multiple Myeloma Market Growth Strategy
Table 26. Main Points Interviewed from Key Monoclonal Antibody for Multiple Myeloma Players
Table 27. Global Monoclonal Antibody for Multiple Myeloma Revenue by Players (2015-2020) (Million US$)
Table 28. Global Monoclonal Antibody for Multiple Myeloma Market Share by Players (2015-2020)
Table 29. Global Top Monoclonal Antibody for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Monoclonal Antibody for Multiple Myeloma as of 2019)
Table 30. Global Monoclonal Antibody for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Monoclonal Antibody for Multiple Myeloma Product Solution and Service
Table 33. Date of Enter into Monoclonal Antibody for Multiple Myeloma Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 36. Global Monoclonal Antibody for Multiple Myeloma Market Size Share by Type (2015-2020)
Table 37. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type (2021-2026)
Table 38. Global Monoclonal Antibody for Multiple Myeloma Market Size Share by Application (2015-2020)
Table 39. Global Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 40. Global Monoclonal Antibody for Multiple Myeloma Market Size Share by Application (2021-2026)
Table 41. North America Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 43. North America Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 44. North America Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 45. North America Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 46. North America Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 47. Europe Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 49. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 51. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 53. China Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 54. China Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 55. China Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 56. China Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 57. China Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 58. China Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 59. Japan Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 61. Japan Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 63. Japan Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 67. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 69. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 71. India Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 72. India Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 73. India Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 74. India Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 75. India Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 76. India Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Monoclonal Antibody for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Monoclonal Antibody for Multiple Myeloma Market Share (2019-2020)
Table 79. Central & South America Monoclonal Antibody for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Monoclonal Antibody for Multiple Myeloma Market Share by Type (2015-2020)
Table 81. Central & South America Monoclonal Antibody for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Monoclonal Antibody for Multiple Myeloma Market Share by Application (2015-2020)
Table 83. Bristol Myers Squibb Company Details
Table 84. Bristol Myers Squibb Business Overview
Table 85. Bristol Myers Squibb Product
Table 86. Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 87. Bristol Myers Squibb Recent Development
Table 88. Abbvie Company Details
Table 89. Abbvie Business Overview
Table 90. Abbvie Product
Table 91. Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 92. Abbvie Recent Development
Table 93. Janssen Biotech Company Details
Table 94. Janssen Biotech Business Overview
Table 95. Janssen Biotech Product
Table 96. Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 97. Janssen Biotech Recent Development
Table 98. Karyopharm Therapeutics Company Details
Table 99. Karyopharm Therapeutics Business Overview
Table 100. Karyopharm Therapeutics Product
Table 101. Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 102. Karyopharm Therapeutics Recent Development
Table 103. PDL BioPharma Company Details
Table 104. PDL BioPharma Business Overview
Table 105. PDL BioPharma Product
Table 106. PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 107. PDL BioPharma Recent Development
Table 108. Roche Company Details
Table 109. Roche Business Overview
Table 110. Roche Product
Table 111. Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 112. Roche Recent Development
Table 113. Seattle Genetics Company Details
Table 114. Seattle Genetics Business Overview
Table 115. Seattle Genetics Product
Table 116. Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2015-2020) (Million US$)
Table 117. Seattle Genetics Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Monoclonal Antibody for Multiple Myeloma Market Share by Type: 2020 VS 2026
Figure 2. Elotuzumab Features
Figure 3. Daratumumab Features
Figure 4. Siltuximab Features
Figure 5. Dacetuzumab Features
Figure 6. Rituximab Features
Figure 7. Other Features
Figure 8. Global Monoclonal Antibody for Multiple Myeloma Market Share by Application: 2020 VS 2026
Figure 9. Hospital Case Studies
Figure 10. Drug Center Case Studies
Figure 11. Clinic Case Studies
Figure 12. Other Case Studies
Figure 13. Monoclonal Antibody for Multiple Myeloma Report Years Considered
Figure 14. Global Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Monoclonal Antibody for Multiple Myeloma Market Share by Regions: 2020 VS 2026
Figure 16. Global Monoclonal Antibody for Multiple Myeloma Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Monoclonal Antibody for Multiple Myeloma Market Share by Players in 2019
Figure 19. Global Top Monoclonal Antibody for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Monoclonal Antibody for Multiple Myeloma as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Monoclonal Antibody for Multiple Myeloma Revenue in 2019
Figure 21. North America Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bristol Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Bristol Myers Squibb Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 30. Abbvie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Abbvie Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 32. Janssen Biotech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Janssen Biotech Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 34. Karyopharm Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Karyopharm Therapeutics Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 36. PDL BioPharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. PDL BioPharma Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 38. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Roche Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 40. Seattle Genetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Seattle Genetics Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2015-2020)
Figure 42. Bottom-up and Top-down Approaches for This Report
Figure 43. Data Triangulation
Figure 44. Key Executives Interviewed